Patents Assigned to Universite de Montpellier
  • Publication number: 20190367670
    Abstract: The present invention relates to new biopolymer, i.e. bioorganic nylons incorporating peptidic blocks obtained by a process of polymerization of amino peptidic blocks. The process of the invention comprises the steps of mixing amino peptidic blocks with or without a diaminoalcane and reacting the mixture according to polycondensation with a diacyl chloride in homogeneous or heterogeneous media.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 5, 2019
    Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean Martinez, Ahmad Mehdi, Gilles Subra, Saïd Jebors
  • Patent number: 10483720
    Abstract: A laser device is provided for generating a helical-shaped optical wave and includes: (i) a gain region located between one first end defined by a first mirror and a second end defined by an exit region, (ii) a second mirror arranged so as to form with the first mirror an optical cavity including the gain region and a gap between the exit region and the second mirror, (iii) apparatus for pumping the gain region so as to generate the optical wave, wherein the laser device further includes at least one apparatus for shaping the light intensity and/or phase profiles of the optical wave and arranged for selecting at least one rotary-symmetrical transverse mode of the optical wave, the rotary-symmetrical transverse mode being chosen between those with a radial index equal to zero and with an azimuthal index being an integer with a module higher or equal to 1.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: November 19, 2019
    Assignees: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Arnaud Garnache-Creuillot, Mikhael Myara, Isabelle Sagnes, Luc Le Gratiet, Mohammed Sellahi, Mohammed Seghilani, Philippe Lalanne
  • Publication number: 20190310191
    Abstract: The invention relates to a device (1) for detecting the presence of determined molecules, comprising, one on top of the other: a first substrate layer (11), a second reflection layer (12), and a third dielectric layer (13). The invention is characterised by an antenna array (14) with conductive parts (143), repeating in one direction (D, D2), the network (14) forming a plasmonic resonator (140) that can be brought into contact with the molecules and arranged so as to emit at least one thermal radiation peak corresponding to at least one characteristic mode of thermal vibration of the determined molecules.
    Type: Application
    Filed: October 23, 2017
    Publication date: October 10, 2019
    Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thierry Taliercio, Laurent Cerutti
  • Publication number: 20190294942
    Abstract: An assembly that includes a plurality of articles, passive or semi-passive RFID tags arranged on the articles, each including at least one unique identifier, in particular recorded in a non-rewritable memory, the tag being configured to transmit, when interrogated, at least the unique identifier of the tag, and a hub including at least one RFID reader, present within the articles, with articles arranged on either side of the hub along at least two directions of an orthonormal reference frame associated with the hub, the latter being arranged in such a way as to be able, by at least one reading antenna, to interrogate at least the RFID tags of articles arranged in said directions, the hub being configured to receive data from the interrogated RFID tags.
    Type: Application
    Filed: November 24, 2017
    Publication date: September 26, 2019
    Applicants: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Brice SORLI, Arnaud VENA
  • Patent number: 10414867
    Abstract: The present invention relates to a cross-linkable composition comprising: i) a fluorinated ?,?-bis(propargyl) oligomer of formula (I): in which m is 1 to 100, e.g. 1 to 93, n is 2 to 150, e.g. 1 to 128, p is 0 to 2, preferably 0 or 1.75, and n, m and p are selected such that the fluorinated ?,?-bis(propargyl) oligomer of formula (I) has a number average molar mass Mn of 400 to 25000; ii) a cross-linking agent comprising at least three azide-N3 groups; and iii) optionally, a fluorinated oligomer comprising two terminal azide-N3 or fluorinated ?,?-bis(azide) oligomer groups. The invention also relates to a material comprising the click chemistry reaction product of the cross-linkable composition of the invention, to a method for preparing said material and to the uses thereof.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 17, 2019
    Assignees: SAFRAN ELECTRICAL & POWER, UNIVERSITE DE MONTPELLIER, Centre National De La Recherche Scientifique (CNRS)
    Inventors: Mathieu Charlas, Donatien Henri Edouard Martineau, Gerald Pierre Maurice Lopez, Jean-Pierre Habas, Bruno Ameduri
  • Patent number: 10414041
    Abstract: A platform for a parallel robot, for acting on an object, including: at least two frames comprising at least two pairs of swivels; at least two bridges that are connected to each of the frames respectively by four hinges which are substantially parallel to an axial direction (V); and a base to be connected to an effector, which is suitable for acting on the object. The base is connected to each bridge respectively by at least one hinge which is oriented along a connection axis which is substantially parallel to the axial direction.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: September 17, 2019
    Assignees: UNIVERSITÉ DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Sébastien Krut, Olivier Company, Francois Pierrot
  • Patent number: 10407480
    Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: September 10, 2019
    Assignees: VIB VZW, UNIVERSITEIT GENT, UNIVERSITÉ DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
  • Publication number: 20190115728
    Abstract: The invention relates to a quantum cascade laser (300) comprising a gain region (102) inserted between two optical confinement layers (1041, 1042), said gain region (102) having an electron input into the gain region (102) and an electron output from said gain region (102) characterized in that said laser comprises a hole-blocking area (304) on the side of said electron output.
    Type: Application
    Filed: March 2, 2017
    Publication date: April 18, 2019
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Roland Tessier, Alexei Baranov
  • Patent number: 10253020
    Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: April 9, 2019
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Pierre Roux, Romain Najman, Didier Scherrer, Carsten Brock, Nathalie Cahuzac, Gilles Gadea, Noelie Campos, Aude Garcel, Julien Santo
  • Patent number: 10238680
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 26, 2019
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
  • Publication number: 20190050535
    Abstract: The present invention relates to a method for classifying a measurement biological sample, comprising: acquisition of at least one DNA melting curve of the measurement biological sample, called at least one measurement curve; and determination that the measurement biological sample belongs to a defined group among different possible groups, by analysis of descriptors originating from the at least one measurement curve, characterized in that the descriptors comprise one or more points of the first derivative of each measurement curve and/or comprise one or more points of the second derivative of each measurement curve and/or one or more points of each measurement curve and/or one or more percentiles of each measurement curve. The invention also relates to a device implementing this method.
    Type: Application
    Filed: January 23, 2017
    Publication date: February 14, 2019
    Applicants: UNIVERSITE DE MONTPELLIER, INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean-Christophe Avarre, Christelle Reynes
  • Patent number: 10196455
    Abstract: The present disclosure relates to neuregulin (NRG)-non competitive allosteric anti-human-HER3 antibodies and uses thereof in diagnostic and therapeutic methods.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: February 5, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: Thierry Chardes, Nadege Gaborit, Christel Larbouret, Andre Pelegrin
  • Publication number: 20190022037
    Abstract: Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.
    Type: Application
    Filed: October 5, 2018
    Publication date: January 24, 2019
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal TAZI, David GRIERSON, Florence MAHUTEAU-BETZER, Pierre ROUX
  • Patent number: 10184150
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to in vitro non-invasive methods for determining the quality of an embryo by determining the level of the cell free nucleic acids or miR-29a or let7-b in the nucleic acid extract from a follicular fluid sample.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 22, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Samir Hamamah, Elodie Scalici, Sabine Traver
  • Patent number: 10179816
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: January 15, 2019
    Assignees: LABOTATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ICM INSTITUT REGIONAL DU CANCER DE MONTPELLIER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • Publication number: 20190011263
    Abstract: The present disclosure generally relates to methods and devices for determining the attitude of a spacecraft by capturing a photograph of a starry sky, determining at least one potential star from the photograph, extracting for at least one potential star a spot pattern based upon rings having a similar area, searching a database for selecting a list of best candidate stars, verifying if the spot may be positively identified as a reference star by matching the spot with best candidate reference stars from a database, positively identifying at least one potential star, and determining the attitude of the spacecraft based upon at least one positively identified star.
    Type: Application
    Filed: December 16, 2016
    Publication date: January 10, 2019
    Applicants: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Andrey Khorev, Lionel Torres
  • Patent number: 10174380
    Abstract: The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein ?i represent the regression ? coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=?1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HASR v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HASR or concluding that the patient will no
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 8, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Montpellier, Centre Hospitalier Universitaire de Montpellier
    Inventors: Jerome Moreaux, Bernard Klein
  • Patent number: 10174115
    Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUD
    Inventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
  • Publication number: 20190002888
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 3, 2019
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean VALMIER
  • Patent number: 10166530
    Abstract: Disclosed is a method for reducing organic compounds using catalysts containing nickel (0) from metal hyperaccumulator plants. The method can be implemented in a green manner and is advantageous compared to methods using the known catalysts.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: January 1, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIER
    Inventors: Claude Grison, Vincent Escande